Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies
| Autor: | Tim Failes, Meera Warby, Marie Wong, Emily Mould, Andrew J. Gifford, Jayne Murray, Carmela De Santo, Klaartje Somers, Olga B. Chernova, Toby Trahair, Jamie I. Fletcher, Andrei V. Gudkov, Tracey A. O'Brien, Katerina Gurova, Michelle J. Henderson, Laura D. Gamble, Lin Xiao, Murray D. Norris, Maria Tsoli, Glenn M. Marshall, Kathryn Evans, Loretta Lau, Lioubov G. Korotchkina, Ruby Pandher, Richard B. Lock, Denise Yu, Anthony J. Cesare, Mark J. Cowley, Paul G Ekert, Laura Franshaw, Anahid Ehteda, Greg M. Arndt, Marie-Emilie A. Gauthier, Jinhan Xie, Katherine M. Tucker, Paulette Barahona, Sumanth Nagabushan, Aisling O'Connor, Paul Cheng, Amit Kumar, Dylan Grebert-Wade, Aaminah Khan, Alexandra Sherstyuk, Patrick Strong, Chelsea Mayoh, Noemi Fuentes Bolanos, David S. Ziegler, Michelle Haber, Mark R. Burns, David Thomas, Dong Anh Khuong Quang, Francis Mussai, Alvin Kamili, Vanessa Tyrrell |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
Oncology Cancer Research medicine.medical_specialty business.industry media_common.quotation_subject Precision medicine medicine.disease Pediatric cancer Clinical trial Efficacy Leukemia chemistry.chemical_compound chemistry Internal medicine Panobinostat Neuroblastoma medicine business media_common |
| Zdroj: | Cancer Research. 80:IA13-IA13 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | Despite the increase in overall child cancer survival rates, pediatric malignancies such as high-risk neuroblastoma, high-risk leukemias (including MLL-translocated infant ALL), and aggressive brain tumors (including DIPG) remain refractory to current multimodal therapies. We have been developing new treatment approaches for these aggressive childhood cancers by (i) utilizing novel targeted therapies either alone or combined with other new agents or established chemotherapeutic drugs, and (ii) by developing new drugs that target key pathways in these child cancers. In neuroblastoma, we have targeted polyamines, showing that combined inhibition of polyamine synthesis by the ODC1 inhibitor DFMO, and of polyamine uptake using the small-molecule drug AMXT 1501, is highly effective at inhibiting tumor growth in Th-MYCN transgenic mice. This combination also shows great efficacy in preclinical models of DIPG, and clinical trials for these diseases are now being planned. We are also targeting metabolism of arginine, the precursor of ornithine, using the pegylated-recombinant arginase BCT-100, which significantly delays tumor development and prolongs survival of neuroblastoma-prone Th-MYCN mice. We have further shown that combining BCT-100 with either DFMO or conventional chemotherapy results in increased survival benefit. CBL0137 is a nontoxic novel anticancer drug currently in phase I trial for adult refractory and relapsed cancers. CBL0137 destabilizes nucleosomes and traps histone chaperone FACT into chromatin, thereby modulating several anticancer mechanisms. We have shown that CBL0137 is effective in mouse models of neuroblastoma, MLL-rearranged leukemia, and DIPG, and that its action is potentiated by the HDAC inhibitor, panobinostat. Moreover, we have developed OT-82, a novel nontoxic NAMPT inhibitor with impressive anticancer activity against mouse models of high-risk childhood ALL, potentiating standard-of-care drugs, and showing similar efficacy as the three-drug induction-type treatment used for pediatric ALL. In addition, for all Australian children with high-risk malignancies, we have developed the Zero Childhood Cancer national precision medicine program. ZERO utilizes whole-genome and whole-transcriptome sequencing, methylation profiling, and where possible, in vitro and in vivo drug testing. To date (July 2019), 74% of 207 patients on the national clinical trial have received a Multidisciplinary Tumor Board recommendation (therapy, germline referral, or change of diagnosis), and of 25 patients with evaluable response data thus far who have received the ZERO recommended therapy, a significant proportion have had a complete response, partial response, or maintained stable disease. Moreover, early experience with drug efficacy studies suggests these data may corroborate genomic therapeutic recommendations and may also identify unanticipated active therapeutics. Citation Format: Michelle Haber, Laura Gamble, Lin Xiao, Ruby Pandher, Klaartje Somers, Jayne Murray, Aaminah Khan, Denise Yu, Laura Franshaw, Mark R. Burns, Maria Tsoli, Anahid Ehteda, Anthony Cesare, Aisling O’Connor, Francis Mussai, Carmela de Santo, Paul Cheng, Lioubov Korotchkina, Katerina Gurova, Vanessa Tyrrell, Emily Mould, Loretta Lau, Dong Anh Khuong Quang, Chelsea Mayoh, Greg Arndt, Paulette Barahona, Tim Failes, Jamie Fletcher, Noemi Fuentes- Bolanos, Marie-Emilie Gauthier, Andrew Gifford, Dylan Grebert-Wade, Alvin Kamili, Amit Kumar, Sumanth Nagabushan, Tracey O’Brien, Patrick Strong, Alexandra Sherstyuk, David Thomas, Toby Trahair, Katherine Tucker, Meera Warby, Marie Wong, Jinhan Xie, Kathryn Evans, Richard Lock, Olga B. Chernova, Michelle Henderson, Andrei V Gudkov, Paul Ekert, Mark J. Cowley, Glenn M. Marshall, David S. Ziegler, Murray D. Norris. Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr IA13. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|